Skip to content
Diabetes & Weight — Dual GIP/GLP-1 agonistsATC A10BX16

Tirzepatide

Prescription only

Weekly dual-hormone injection with the largest weight loss of any approved drug.

Starts working
Varies
Half-life
About 5 days
In use since
2022
Pregnancy
Usually avoided

Overview

Tirzepatide acts on two gut-hormone receptors (GIP and GLP-1). Sold as Mounjaro and Zepbound, it lowers blood sugar strongly and produced around 20% average weight loss at the top dose in trials. It's also approved for obstructive sleep apnoea with obesity.

Conditions it's used for

How it works

Copies two gut hormones that control insulin, appetite and fat storage.

Tirzepatide belongs to the Dual GIP/GLP-1 agonists. How Dual GIP/GLP-1 agonists work: combine the effects of two incretin hormones on insulin, appetite and fat metabolism.

Uses

  • Type 2 diabetes
  • Obesity and overweight with health problems
  • Obstructive sleep apnoea with obesity

Available as: weekly pen or vial injection.

Typical dose

Adults
Start 2.5 mg weekly, increasing by 2.5 mg every 4 weeks to 5–15 mg.

Typical doses for orientation only. Your prescription, the pack leaflet and local guidance take priority.

Side effects

Common

Often mild and may settle with time

  • Nausea
  • Diarrhoea
  • Vomiting
  • Constipation
  • Reduced appetite

Serious — get medical help

Uncommon, but need prompt attention

  • Pancreatitis
  • Gallbladder disease
  • Dehydration and kidney injury
  • Aspiration under anaesthesia

Warnings

  • Can make the oral contraceptive pill less reliable — use a barrier method for 4 weeks after starting and each dose increase
  • Same thyroid cancer precautions as GLP-1 drugs
  • Avoid unregulated versions

Interactions

  • Oral contraceptives — reduced reliability
  • Insulin and sulfonylureas — hypos
Check Tirzepatide against your own medicines

Pregnancy and breastfeeding

Usually avoided

Stop at least 1 month before trying to conceive.

Breastfeeding advice can differ from pregnancy advice — check with a pharmacist, or the LactMed database.

Brand names

United States
Mounjaro, Zepbound
United Kingdom
Mounjaro
India
Mounjaro
Australia
Mounjaro

Examples only; many generic versions exist. The same brand name can mean different products in different countries.

History

  1. 2022

    Mounjaro approved in the US for type 2 diabetes.

  2. 2023

    Zepbound approved for weight management.

  3. 2024

    Approved for obstructive sleep apnoea with obesity.

  4. 2025

    Launched in India; SURMOUNT-5 shows about 20% weight loss versus 14% with semaglutide.

Common questions

Is it stronger than semaglutide?

In a head-to-head trial it produced more weight loss on average, though individual responses vary.

Do I need a prescription for Tirzepatide?

Yes — Tirzepatide is prescription-only in most countries.

Can I take Tirzepatide during pregnancy?

Usually avoided. Stop at least 1 month before trying to conceive. Always check with a doctor or midwife.

Sources and official information

Entry last reviewed October 2026. Compiled from WHO, NHS, FDA/DailyMed, BNF and national formulary information. How we write entries.